Rosie H. Taylor

Rosie H. Taylor

Auto-generated profile, based on publicly available information

Rosie H. Taylor

King’s College London

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2023 in Expert Opinion on Pharmacotherapy
Verified
Journal Article
Open access
MKMichail Kalfas
Michail Kalfas
RTRosie H. Taylor
Rosie H. Taylor
DTDimosthenis Tsapekos
Dimosthenis Tsapekos
Allan YoungAllan Young
Allan Young
A new era of treatment for adults with treatment-resistant depression (TRD), which involves psychedelic substances, is dawning. Emerging evidence indicates that psychedelics can exert antidepressant effects through multiple neurobiological and psychological mechanisms. However, it remains to be seen if these new treatments will revolutionize the treatment of TRD. The present review focuses on the efficacy of classic serotoninergic psychedelics psilocybin, lysergic acid diethylamide (LSD), 5-Methoxy-N,N-dimethyltryptamine (DMT), ayahuasca and mescaline (3,4,5-trimethoxyacetonitrile), as well as 3,4-methylenedioxymethamphetamine (MDMA), for TRD. A systematic search was conducted for psilocybin in TRD as emerging trials had not yet been subject to review. A narrative review summarized findings on other psychedelics. Psychedelic therapy has created a paradigm shift in the treatment of TRD, as it can maximize therapeutic benefits and minimize potential risks. Psilocybin holds promise as a potential game-changer in the treatment of TRD, with initial evidence suggesting a rapid antidepressant effect sustained for some responders for at least 3 months. Nevertheless, further adequately powered, double-blind, comparator-controlled trials are required to explore and clarify the mechanisms of action and long-term effects of psychedelics in TRD. Psychedelics also hold promise for other psychiatric conditions, such as bipolar depression and post-traumatic stress disorder.

25 May 2023 in BJPsych Open
Verified
Journal Article
Open access
PDF file
AUAndrea Ulrichsen
Andrea Ulrichsen
EHElliot Hampsey
Elliot Hampsey
RTRosie H. Taylor
Rosie H. Taylor
RGRomayne Gadelrab
Romayne Gadelrab
RSRebecca Strawbridge
Rebecca Strawbridge
Allan YoungAllan Young
Allan Young
Background: Lithium has long been recognised as an effective treatment for bipolar disorder. Its relative efficacy has been measured with a diverse range of clinical outcomes, resulting in differences in efficacy reporting that have not been systematically reviewed. Aims: We aimed to identify and compare the various measures of lithium efficacy employed in interventional studies for people with bipolar disorder. Method: Database (PubMed, Web of Science) and hand searches were performed to identify studies that assessed a clinical response in patients with bipolar disorder who received lithium, up to the end of 2021. We included primary human interventional studies without excluding specific study designs, bipolar disorder subtypes, duration or dosage of lithium treatment. Continuous outcome effects were meta-analysed; binary outcomes were synthesised visually and narratively. The Cochrane risk-of-bias tool was used to assess study-level risk of bias. Results: Seventy-one studies were included (N = 30 542). Approximately two-thirds of participants attained a clinically significant improvement in manic or depressive symptoms, and over 50% achieved remission. About a third required hospital admission (study length 2–12 years) and around 50% needed further treatment to stay well or had recurrence of symptoms; the latter two outcomes tended to be assessed over long-term maintenance periods. Conclusions: An abundance of measurements have been used to assess lithium's clinical effects, across several study designs. Despite the resultant high heterogeneity, an overall picture of lithium's effects emerges that supports previous literature; between half and two-thirds of patients respond well to lithium across varying outcome measures, baseline mood states, study durations and bipolar disorder subtypes.